Shares of GlaxoSmithKline (NYSE:GSK) have been assigned an average rating of “Hold” from the seventeen research firms that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, ten have given a hold rating and five have issued a buy rating on the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $40.00.
GSK has been the subject of several analyst reports. Kepler Capital Markets raised shares of GlaxoSmithKline from a “reduce” rating to a “hold” rating in a report on Friday, February 9th. Zacks Investment Research cut shares of GlaxoSmithKline from a “buy” rating to a “hold” rating in a report on Wednesday, January 10th. Cowen reissued a “hold” rating and set a $40.00 price target on shares of GlaxoSmithKline in a report on Thursday, February 15th. ValuEngine cut shares of GlaxoSmithKline from a “buy” rating to a “hold” rating in a report on Friday, February 2nd. Finally, JPMorgan Chase reissued a “neutral” rating on shares of GlaxoSmithKline in a report on Thursday, January 11th.
Shares of NYSE:GSK traded up $0.12 on Friday, reaching $40.00. The company’s stock had a trading volume of 2,924,227 shares, compared to its average volume of 3,465,769. GlaxoSmithKline has a 52-week low of $34.52 and a 52-week high of $44.53. The company has a debt-to-equity ratio of 4.09, a quick ratio of 0.39 and a current ratio of 0.60. The stock has a market capitalization of $99,177.36, a price-to-earnings ratio of 13.89, a PEG ratio of 2.13 and a beta of 0.84.
The company also recently declared a quarterly dividend, which was paid on Thursday, April 12th. Investors of record on Friday, February 23rd were issued a dividend of $0.633 per share. This is a boost from GlaxoSmithKline’s previous quarterly dividend of $0.50. This represents a $2.53 annualized dividend and a yield of 6.33%. The ex-dividend date was Thursday, February 22nd. GlaxoSmithKline’s dividend payout ratio is currently 89.93%.
A number of institutional investors and hedge funds have recently modified their holdings of the business. Profund Advisors LLC grew its position in GlaxoSmithKline by 3.0% during the fourth quarter. Profund Advisors LLC now owns 52,264 shares of the pharmaceutical company’s stock worth $1,854,000 after buying an additional 1,519 shares during the period. Atria Investments LLC grew its position in GlaxoSmithKline by 17.1% during the fourth quarter. Atria Investments LLC now owns 12,830 shares of the pharmaceutical company’s stock worth $455,000 after buying an additional 1,874 shares during the period. Canandaigua National Bank & Trust Co. grew its position in GlaxoSmithKline by 14.6% during the fourth quarter. Canandaigua National Bank & Trust Co. now owns 15,297 shares of the pharmaceutical company’s stock worth $543,000 after buying an additional 1,950 shares during the period. Hoertkorn Richard Charles grew its position in GlaxoSmithKline by 4.5% during the fourth quarter. Hoertkorn Richard Charles now owns 48,075 shares of the pharmaceutical company’s stock worth $1,705,000 after buying an additional 2,050 shares during the period. Finally, IFC Holdings Incorporated FL grew its position in shares of GlaxoSmithKline by 15.2% in the fourth quarter. IFC Holdings Incorporated FL now owns 15,744 shares of the pharmaceutical company’s stock valued at $560,000 after purchasing an additional 2,079 shares during the last quarter. Institutional investors own 10.96% of the company’s stock.
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.